Seeking pediatric subjects have been diagnosed with Type 2 Diabetes.

Enroll Now

Type of Study:

Pediatric Type 2

Title of Study:

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

Short Title:

Seeking pediatric subjects have been diagnosed with Type 2 Diabetes.

Study Length: 26 Weeks

Target Age/Sex: 10-17, Male and Female

Benefits:

Participants will receive at no cost: Study medication, Study related lab work and medical exams. Subject will also receive a stipend for time/travel related to the study.

Link: ClinicalTrials.gov